Intrexon, which is developing synthetic biology technologies, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering. The Germantown, MD-based company, which was founded in 1998 and booked $16 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NYSE under the symbol XON. Intrexon initially filed confidentially on May 10, 2013. J.P. Morgan and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
